World of DTC Marketing

SEPTEMBER 7, 2022

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Their future model includes helping HCPs rather than trying to sell to them. Wall Street wants growth, as do investors, but that may be impossible for pharmaceutical companies.

Pharma 210

Pharma Food and Drug Administration Marketing Prescription 210

PM360

NOVEMBER 27, 2023

Using Amazon Bedrock and Amazon Textract, disparate datasets are aggregated and tagged, reducing time and effort throughout the process while providing an accurate and expedited user experience. Leaders from AWS and EVERSANA will be at the AWS re:Invent Conference, November 27-30, 2023 , in Las Vegas.

Medical 52

Medical Education Healthcare Healthcare 52

PM360

OCTOBER 13, 2023

Another capability made possible by fine-tuning is the enhancement of content tagging. Content tagging has always been a labor-intensive task. Auto-tagging ensures that the right content efficiently reaches the right customers. Fine-tuning models can target domains and generate prompts to tag the content into relevant topics.

Marketing 64

Marketing Specialization Healthcare Healthcare 64

PM360

NOVEMBER 12, 2023

And how can they determine what data will lead to the most meaningful change for their campaigns, healthcare professionals (HCPs), and ultimately patients? So, how can marketers get the most out of all of this data? Dr. Marks says it helps to have the right people in place.

Marketing 59

Marketing Media Patients Healthcare 59

PM360

APRIL 22, 2024

Gone are the days when Medical Affairs merely acted as a liaison between pharmaceutical companies and healthcare professionals (HCPs). Driving an Integrated Evidence Strategy Evidence-based decision-making and differentiation are of paramount importance for HCPs who are flooded with therapy options or are circumspect to adopt a new therapy.

Medical 52

Medical Healthcare Healthcare Education 52

PM360

APRIL 7, 2023

It’s never too early in the research and development (R&D) process to identify and measure a product’s projected clinical outcomes in order to meet the needs and expectations of payers and healthcare professionals (HCPs) who are the final arbiters of a product’s commercial success. million for the new hemophilia gene therapy.

Manufacturing 52

Manufacturing Marketing Patients Safety 52